Lithium;3-[(1-azabicyclo[2.2.2]octan-3-ylamino)methyl]-1-benzylindazole-4-carboxylic acid;hydride
C23H27LiN4O2 — CID 173016688
Data last refreshed: (MolForge compound catalog, from PubChem)
About Lithium;3-[(1-azabicyclo[2.2.2]octan-3-ylamino)methyl]-1-benzylindazole-4-carboxylic acid;hydride
Lithium;3-[(1-azabicyclo[2.2.2]octan-3-ylamino)methyl]-1-benzylindazole-4-carboxylic acid;hydride (PubChem CID 173016688) has the molecular formula C23H27LiN4O2 and a molecular weight of 398.44 g/mol. Its IUPAC name is lithium;3-[(1-azabicyclo[2.2.2]octan-3-ylamino)methyl]-1-benzylindazole-4-carboxylic acid;hydride.
Molecular Properties
| Compound Name | Lithium;3-[(1-azabicyclo[2.2.2]octan-3-ylamino)methyl]-1-benzylindazole-4-carboxylic acid;hydride |
|---|---|
| PubChem CID | 173016688 |
| Molecular Formula | C23H27LiN4O2 |
| Molecular Weight | 398.44 g/mol |
| Exact Mass | 398.23 |
| IUPAC Name | lithium;3-[(1-azabicyclo[2.2.2]octan-3-ylamino)methyl]-1-benzylindazole-4-carboxylic acid;hydride |
| SMILES | O=C(O)c1cccc2c1c(CNC1CN3CCC1CC3)nn2Cc1ccccc1.[H-].[Li+] |
| InChI | InChI=1S/C23H26N4O2.Li.H/c28-23(29)18-7-4-8-21-22(18)19(25-27(21)14-16-5-2-1-3-6-16)13-24-20-15-26-11-9-17(20)10-12-26;;/h1-8,17,20,24H,9-15H2,(H,28,29);;/q;+1;-1 |
| InChIKey | FDSRNYHRIDJFKG-UHFFFAOYSA-N |
| XLogP | 0.08 |
| TPSA | 70.39 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 5 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 30 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 398.44 |
| LogP ≤ 5 | 0.08 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 5 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 173016688 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.